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Ischemic stroke cause remains undetermined in 30% of cases, leading to a diagnosis ofDenve
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i.org/1cryptogenic stroke. Paroxysmal atrial ﬁbrillation (AF) is a major cause of ischemic stroke
but may go undetected with short periods of ECG monitoring. The Cryptogenic Stroke and
Underlying Atrial Fibrillation trial (CRYSTAL AF) demonstrated that long-term electro-
cardiographic monitoring with insertable cardiac monitors (ICM) is superior to conven-
tional follow-up in detecting AF in the population with cryptogenic stroke. We evaluated
the sensitivity and negative predictive value (NPV) of various external monitoring tech-
niques within a cryptogenic stroke cohort. Simulated intermittent monitoring strategies
were compared to continuous rhythm monitoring in 168 ICM patients of the CRYSTAL
AF trial. Short-term monitoring included a single 24-hour, 48-hour, and 7-day Holter and
21-day and 30-day event recorders. Periodic monitoring consisted of quarterly monitoring
through 24-hour, 48-hour, and 7-day Holters and monthly 24-hour Holters. For a single
monitoring period, the sensitivity for AF diagnosis was lowest with a 24-hour Holter (1.3%)
and highest with a 30-day event recorder (22.8%). The NPV ranged from 82.3% to 85.6%
for all single external monitoring strategies. Quarterly monitoring with 24-hour Holters had
a sensitivity of 3.1%, whereas quarterly 7-day monitors increased the sensitivity to 20.8%.
The NPVs for repetitive periodic monitoring strategies were similar at 82.6% to 85.3%.
Long-term continuous monitoring was superior in detecting AF compared to all intermit-
tent monitoring strategies evaluated (p <0.001). Long-term continuous electrocardiographic
monitoring with ICMs is signiﬁcantly more effective than any of the simulated intermittent
monitoring strategies for identifying AF in patients with previous cryptogenic
stroke.  2015 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am
J Cardiol 2015;116:889e893)Multiple studies have used a variety of cardiac monitors
for atrial ﬁbrillation (AF) detection after cryptogenic stroke
and detection rates range from 0% to 25%.1e12 Differences
in study design and absence of control groups have made
interpretation of these results difﬁcult and have limited the
application of these studies in clinical practice. As a result,
there are no ﬁrm recommendations on the duration of AF
monitoring in a population with ischemic stroke beyond
24 hours. The Cryptogenic Stroke and Underlying Atrial
Fibrillation trial (CRYSTAL AF) compared the rate of AF
detection in patients with cryptogenic stroke randomlyr Cardiology Associates, Littleton, Colorado; bBluhm
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0.1016/j.amjcard.2015.06.012assigned to either conventional follow-up (control) or
continuous monitoring with an insertable cardiac monitor
(ICM, Reveal XT; Medtronic, Minneapolis, Minnesota).13
At 6, 12, and 36 months, the rates of AF detection were
8.9%, 12.4%, and 30% in the continuous monitoring arm
versus 1.4%, 2.0%, and 3.0% in the control arm, respec-
tively (p <0.001 for all).2 Given the invasive nature and cost
associated with device insertion, the question remains
whether currently available forms of external monitoring
can substitute for the long-term continuous monitoring
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Figure 1. Simulation strategies for one-time and repetitive periodic external
monitoring. The black squares represent the follow-up day(s) that were
selected for external monitoring by considering device data from only that
subset of days. For simplicity, the initial day of monitoring is shown as day
1 but was actually selected at random from a uniform distribution among
the ﬁrst 14 days after ICM insertion. For repetitive periodic monitoring
strategies, subsequent monitoring periods were chosen a ﬁxed number of
days from the initial monitoring period.
Figure 2. Consort diagram. Of 221 patients randomized to the ICM arm in
the CRYSTAL AF study, a total of 168 patients met the criteria for
inclusion in this subanalysis.
Table 1
Baseline characteristics (n ¼ 168)
Variable
Age (years) 61.3  11.0
Men 115 (68%)
Index Event e Stroke 150 (89%)
Index Event e Transient Ischemic Attack 18 (11%)
CHADS2 Score (mean) 2.9  0.8
2 54 (32%)
3 75 (45%)
4 35 (21%)
5 3 (2%)
6 1 (1%)
Heart Failure 5 (3%)
Hypertension 106 (63%)
Diabetes Mellitus 22 (13%)
890 The American Journal of Cardiology (www.ajconline.org)assess the sensitivity and negative predictive value (NPV) of
various simulated durations and periodicities of external
monitoring strategies for AF detection in a population with
cryptogenic stroke.
Methods
The design of the CRYSTAL AF study has been previ-
ously published.13 Brieﬂy, patients aged >40 years who
presented with a cryptogenic stroke or transient ischemic
attack (TIA) within 90 days were included. They were
randomized within 14 days to conventional follow-up or
ICM. Patients with history of AF or atrial ﬂutter were
excluded. Patients were also excluded if there was a per-
manent indication or contraindication to anticoagulation or
if they needed or had a pacemaker or implantable car-
dioverter deﬁbrillator. Device data from days 1 to 345 after
insertion were evaluated for the purposes of this analysis.
In the CRYSTAL AF study, AF was deﬁned as an
episode of irregular heart rhythm without detectable
p-waves lasting >30 seconds in duration. AF episodes were
independently adjudicated. In this analysis, we simulated
several intermittent monitoring strategies and compared
them to continuous rhythm monitoring with an ICM in the
intervention arm of the CRYSTAL AF trial. These inter-
mittent monitoring strategies, including both single short-
term and repetitive periodic monitoring, are depicted in
Figure 1. Short-term monitoring included 24-hour Holter
monitor, 48-hour Holter monitor, 7-day Holter monitor,
21-day event recorder, and 30-day event recorder. Periodic
monitoring consisted of quarterly monitoring through
24-hour Holter, 48-hour Holter, and 7-day Holter and
monthly 24-hour Holters.
The initial day for each intermittent monitoring strategy
simulation was randomly selected from a uniform distribu-
tion among days 1 to 14 after ICM placement. For example,
to simulate a 7-day Holter monitor, we evaluated whether the
ICM detected AF on any of 7 consecutive days beginning
randomly on days 1 to 14 after device insertion. Formonitoring strategies involving repetitive periodic moni-
toring, all subsequent monitoring periods were based on a
ﬁxed number of days from the randomly selected initial day
of monitoring. For example, quarterly 24-hour Holter
monitoring was simulated by evaluating whether the ICM
detected AF on a randomly selected day within the ﬁrst
14 days after device insertion or on days 90, 180, and 270
from that initially selected day. A minimum follow-up
duration of 345 days was required of all patients to allow
for simulation of the longest monitoring scenario (12
monthly 24-hour Holters) with the latest randomly selected
monitoring start day (day 14). All simulations were repeated
10,000 times, and the mean value of these simulations are
reported.
Figure 3. Sensitivity and NPV of one-time and repetitive periodic external
monitoring for AF detection. Black circles and gray squares represent the
sensitivities and NPVs, respectively, for AF detection with various external
monitoring methods.
Arrhythmias and Conduction Disturbances/AF Monitoring Strategies After Cryptogenic Stroke 891From these simulations, the patient-level sensitivity and
NPV were estimated through comparison with actual AF
events recorded by the ICM as the “gold standard.” Sensi-
tivity measures the proportion of patients with AF detected
by the ICM who would have been identiﬁed as having AF
through intermittent monitoring. NPV measures the pro-
portion of patients without AF detected through intermittent
monitoring who were correctly identiﬁed as being free from
AF through the ICM.
Continuous variables are reported as means with standard
deviations, and categorical variables are reported as fre-
quency counts with percentages. The McNemar test was
used to compare the proportions of patients with AF
detected through intermittent monitoring strategies versus
continuous monitoring. SAS version 9.2 (SAS Institute Inc.,
Cary, North Carolina) was used for all statistical analyses. A
signiﬁcance level of 0.05 was used for all statistical tests.Results
Of the 221 patients who were randomized to the ICM
arm in the CRYSTAL AF trial, 26 patients had their devices
inserted more than 14 days after randomization and an
additional 27 patients did not have data available for anal-
ysis from days 1 to 345 after insertion. Consequently, 168
patients form the basis of this analysis (Figure 2). Baseline
characteristics are provided in Table 1. There were 30 pa-
tients (18%) who were found to have AF with continuous
monitoring within the initial 345 days. The median AF
burden was 0.0336 hours/day (interquartile range [IQR]
0.0114 to 0.1033), and the median percent days with AF
was 5.5% (IQR 2.9 to 18.0). Their median AF duration on
the single day with maximal burden was 3.9 hours (IQR 0.1
to 13.0 hours). Of the 30 patients with AF detected by theICM, 23 patients (77%) had a maximum 1-day AF burden
greater than 6 minutes.
Figure 3 depicts the sensitivity and NPV of one-time
short-term external monitoring for AF detection. The
sensitivity, compared to the ICM, was lowest for a single
24-hour Holter (1.3%) and highest for a 30-day monitor
(22.8%), whereas the NPV ranged from 82.3% to 85.6%.
The results of repetitive periodic monitoring (Figure 3) are
also limited with 4 quarterly 24-hour Holters demonstrating
a sensitivity of 3.1% and 4 quarterly 7-day Holters showing
the greatest sensitivity at 20.8%. The NPV for repetitive
monitoring was 82.6% to 85.3%, similar to the one-time
monitoring strategies. For all the intermittent monitoring
strategies explored in this analysis, both the sensitivity and
NPV were signiﬁcantly lower than that of continuous
arrhythmia monitoring (p <0.001).
Discussion
Given the often asymptomatic and paroxysmal nature of
AF, relying on symptoms14e16 and/or intermittent moni-
toring alone,17,18 will frequently underestimate the presence
and extent of the arrhythmia. With the duration of moni-
toring needed to detect AF inversely proportional to AF
burden, long monitoring periods may be necessary to detect
infrequent but clinically important paroxysms of AF. The
CRYSTAL AF trial, a randomized study comparing ICM to
routine care, demonstrated that the rate of AF detection was
signiﬁcantly higher with continuous long-term monitoring
in this population at 6 months (hazard ratio [HR] 6.4; 95%
conﬁdence interval [CI] 1.9 to 21.7; p <0.001), 12 months
(HR 7.3; 95% CI 2.6 to 20.8; p <0.001), and 36 months
(HR 8.8; 95% CI 3.5 to 22.2; p <0.001).2 Importantly, the
median time to the ﬁrst AF episode was 41 (IQR 14 to 84)
days at 6 months, 84 (IQR 18 to 265) days at 12 months,
and 255 (IQR 42 to 454) days at 36 months. Moreover,
95% of the patients in the ICM arm of CRYSTAL AF who
had AF had at least 1 episode lasting >6 minutes, a
threshold previously shown to be associated with increased
stroke risk.19 Finally, 3/4 of ﬁrst AF episodes in CRYSTAL
AF were asymptomatic, underscoring the unreliable nature
of symptoms in diagnosing AF in these high-risk patients.
On the basis of the current simulation analysis, use of
standard monitoring either singularly or repeatedly would
have a sensitivity of only 1.3% to 22.8% for AF detection,
highlighting the limitations of these approaches for AF
detection.
Previous simulations of variable durations of external
monitors based on data from implanted cardiac devices
yielded vastly different results from our analysis, primarily
because of the differences in baseline AF prevalence in the
sampled cohort. For example, in a study of 574 pacemaker
patients with a known history of AF,17 the estimated
sensitivity of intermittent monitoring (annual, quarterly, and
monthly 24-hour Holter; 7-day and 30-day annual long-term
recordings) was signiﬁcantly higher (range 31% to 71%)
and the NPV signiﬁcantly lower (range 21% to 39%)
compared to the present study. The low AF burden in the
population with cryptogenic stroke reduces the sensitivity of
any and all “short-term” external monitors and highlights
the need for continuous monitoring in this population as a
892 The American Journal of Cardiology (www.ajconline.org)result. Furthermore, the history of previous ischemic stroke
or TIA in the CRYSTAL AF population increases the
importance of ﬁnding and treating AF to prevent subsequent
events.
Guidelines recommend that the evaluation of patients who
present with ischemic stroke should include monitoring for
AF.20 Approximately, 4.3% to 15% of hospitalized patients
will have AF diagnosed during their hospital stay using
continuous electrocardiographic monitoring.3,12,21 The
latest stroke guidelines state that prolonged rhythm moni-
toring (approximately 30 days) looking for AF is reasonable
within 6 months of the index event in patients with TIA or
cerebral vascular accidents with no apparent cause (class IIa,
level of evidence C).20 Previous studies have assessed the
yield of various monitoring techniques for paroxysmal AF in
the population with cryptogenic stroke. External monitors
worn for 24 to 72 hours ﬁnd AF in 2.4% to 6.0% of these
patients.4e6 In a study of 21-day mobile outpatient telemetry,
23% of patients with cryptogenic stroke had AF, but the vast
majority of reported episodes (85%) lasted only a few sec-
onds in duration.7 The 30-Day Cardiac Event Monitor Belt
for Recording Atrial Fibrillation After a Cerebral Ischemic
Event (EMBRACE) trial randomly assigned patients with
cryptogenic ischemic stroke or TIA to either a 30-day event-
triggered recorder or a conventional 24-hour monitor. The
primary outcome was newly detected AF lasting
30 seconds within 90 days after randomization. AF was
detected in 16.1% in the intervention group, compared with
3.2% in the control group.8 Unlike the EMBRACE study,
CRYSTAL AF required a screening transesophageal echo-
cardiogram before the diagnosis of cryptogenic stroke and
had a younger minimum age requirement, factors that may
explain the different ﬁndings in the 2 studies.
Small, noncontrolled trials of ICMs have reported AF
detection rates between 17% and 27% in the population with
cryptogenic stroke.9e11 A meta-analysis of 32 studies by
Kishore et al12 found a diagnosis of AF in 11.5% in this
population. Unfortunately, differences in enrollment criteria,
follow-up duration, and end point deﬁnition make comparison
between any of these studies difﬁcult. Further evaluation is
required to understand whether a hybrid monitoring strategy
incorporating both short-term external devices and long-term
continuous arrhythmia surveillance through ICMs could be
beneﬁcial.
There are several limitations of this simulation study that
deserve mention. The analysis was restricted to patients with
at least 345 days of data to simulate the longest monitoring
scenario of 12 monthly 24-hour Holters. In addition,
although time to the ﬁrst episode of AF, deﬁned as
>30 seconds in duration, was considered the primary end
point of the CRYSTAL AF trial, the devices used in this
study are unlikely to register an AF episode <2 minutes
based on the requirements of the AF detection algorithm.
We also assumed, for the purposes of the simulation, 100%
patient compliance with external monitoring which may
have overestimated the intermittent monitoring results. It
has been shown that patient compliance diminishes as the
nominal monitoring duration increases, owing to concerns
regarding skin irritation and the inconvenience associated
with performing activities of daily living.22,23Acknowledgment: The authors thank Patrice Lerum, BS,
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